MYCN and neuroblastoma: To investigate the role of super-enhancers in neuroblastoma differentiation and to identify differentiation-associated super-enhancers in response to ATRA treatment, we subjected three phenotypically and genetically different neuroblastoma cell lines: MYCN-amplified ADRN cell line, SK-N-BE (2) C (BE2C), MYCN non-amplified ADRN cell line SH-SY5Y, and MYCN non-amplified MES cell line SH-EP, to treatment with ATRA.